Epididymal cystadenomas and epithelial tumourlets:: effects of VHL deficiency on the human epididymis

被引:28
作者
Glaesker, S.
Tran, M. G. B.
Shively, S. B.
Ikejin, B.
Lonser, R. R.
Maxwell, P. H.
Zhuang, Z.
Oldfield, E. H.
Vortmeyer, A. O.
机构
[1] NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA
[2] Univ Freiburg, Neurochirurg Univ Klin, Freiburg, Germany
[3] Univ London Imperial Coll Sci Technol & Med, Renal Sect, Hammersmith Hosp, London W12 0NN, England
[4] George Washington Univ, Mol & Cellular Oncol, Inst Biomed Sci, Washington, DC USA
关键词
von Hippel-Lindau disease; epididymis cystadenoma; tumour suppressor gene; hypoxia-inducible factor;
D O I
10.1002/path.2029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although epididymal cystadenomas (ECAs) are among the most frequent VHL disease-associated tumours, fundamental questions about their pathogenesis have remained unanswered. Classification of ECAs is controversial, and the cell of origin is unknown. It is also unknown whether ECAs - like other VHL disease-associated tumours - arise as a result of VHL gene inactivation, and whether ECAs exhibit subsequent activation of hypoxia-inducible factor HIF. Moreover, the morphological spectrum of earliest ECA formation is unknown. In a detailed molecular pathological analysis of a series of epididymides collected from VHL patients at autopsy, we found that ECAs are true neoplasms that arise secondary to inactivation of the wild-type copy of the VHL gene, followed by early and simultaneous activation of HIFI and HIF2 associated with up-regulation of downstream targets, including CAIX and GLUT-1. The observations also indicate that ECA formation evolves from a variety of microscopic epithelial tumourlets, and that these tumourlets are confined to the efferent ductular system. Although genetic and immunohistocheMical analysis of precursor structures consistently revealed VHL gene inactivation and activation of HIF in the precursor lesions, only a small subset appears to progress into frank cystadenoma. Thus, ECA tumorigenesis in VHL disease shares fundamental principles with tumorigenesis in other affected organ systems. Copyright (c) 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:32 / 41
页数:10
相关论文
共 61 条
[21]  
KRAGEL PJ, 1990, ARCH PATHOL LAB MED, V114, P672
[22]   Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function [J].
Krieg, M ;
Haas, R ;
Brauch, H ;
Acker, T ;
Flamme, I ;
Plate, KH .
ONCOGENE, 2000, 19 (48) :5435-5443
[23]   IDENTIFICATION OF THE VONHIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE [J].
LATIF, F ;
TORY, K ;
GNARRA, J ;
YAO, M ;
DUH, FM ;
ORCUTT, ML ;
STACKHOUSE, T ;
KUZMIN, I ;
MODI, W ;
GEIL, L ;
SCHMIDT, L ;
ZHOU, FW ;
LI, H ;
WEI, MH ;
CHEN, F ;
GLENN, G ;
CHOYKE, P ;
WALTHER, MM ;
WENG, YK ;
DUAN, DSR ;
DEAN, M ;
GLAVAC, D ;
RICHARDS, FM ;
CROSSEY, PA ;
FERGUSONSMITH, MA ;
LEPASLIER, D ;
CHUMAKOV, I ;
COHEN, D ;
CHINAULT, AC ;
MAHER, ER ;
LINEHAN, WM ;
ZBAR, B ;
LERMAN, MI .
SCIENCE, 1993, 260 (5112) :1317-1320
[24]  
Lissens P, 1995, Acta Urol Belg, V63, P109
[25]   The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity [J].
Lisztwan, J ;
Imbert, G ;
Wirbelauer, C ;
Gstaiger, M ;
Krek, W .
GENES & DEVELOPMENT, 1999, 13 (14) :1822-1833
[26]   Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2 [J].
Lonergan, KM ;
Iliopoulos, O ;
Ohh, M ;
Kamura, T ;
Conaway, RC ;
Conaway, JW ;
Kaelin, WG .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (02) :732-741
[27]   von Hippel-Lindau disease [J].
Lonser, RR ;
Glenn, GM ;
Walther, M ;
Chew, EY ;
Libutti, SK ;
Linehan, WM ;
Oldfield, EH .
LANCET, 2003, 361 (9374) :2059-2067
[28]  
Lubensky IA, 1996, AM J PATHOL, V149, P2089
[29]   Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth [J].
Mack, FA ;
Rathmell, WK ;
Arsham, AM ;
Gnarra, J ;
Keith, B ;
Simon, MC .
CANCER CELL, 2003, 3 (01) :75-88
[30]   HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron [J].
Mandriota, SJ ;
Turner, KJ ;
Davies, DR ;
Murray, PG ;
Morgan, NV ;
Sowter, HM ;
Wykoff, CC ;
Maher, ER ;
Harris, AL ;
Ratcliffe, PJ ;
Maxwell, PH .
CANCER CELL, 2002, 1 (05) :459-468